Assessment of human papillomavirus E6/E7 oncogene expression as cervical disease biomarker

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Fontecha, Nerea ^a   Basaras, Miren ^a   Hernáez, Silvia ^b   Andía, Daniel ^b   Cisterna, Ramón ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

Author keywords

Biomarker; E6 E7 mRNA detection; High risk HPV genotypes; Oncogenes; Prognosis marker

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; TUMOR MARKER; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; MIXED INFECTION; ONCOGENE; PAPILLOMAVIRUS INFECTION; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; UTERINE CERVIX DYSPLASIA; GENETICS; METABOLISM; MIDDLE AGED; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; ONCOGENES; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, VIRAL; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84994285975     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2885-x     Document Type: Article

References (31)

1. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000;19(1-2):1-5.
2. Bray F, Ren J, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133-45.
3. Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380(9856):1840-50.
4. de Sanjose S, Quint WGV, Alemany L, Geraets DT, Ellen Klaustermeier J, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56.
5. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer. 2009;45(15):2632-9.
6. Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX, et al. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: The CLEOPATRE study. J Med Virol. 2012;84(6):947-56.
7. Delgado D, Manuel Marin J, de Diego J, Guerra S, Gonzalez B, Barrios JL, et al. Human papillomavirus (HPV) genotype distribution in women with abnormal cervical cytology in the Basque Country, Spain. Enferm Infecc Microbiol Clin. 2012;30(5):230-5.
8. Sjoeborg KD, Trope A, Lie AK, Jonassen CM, Steinbakk M, Hansen M, et al. HPV genotype distribution according to severity of cervical neoplasia. Gynecol Oncol. 2010;118(1):29-34.
9. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2009;125(9):2151-8.
10. Carter J, Koutsky L, Hughes J, Lee S, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181(6):1911-9.
11. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009;384(2):410-4.
12. Wechsler EI, Wang Q, Roberts I, Pagliarulo E, Jackson D, Untersperger C, et al. Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression. J Virol. 2012;86(11):6358-64.
13. von Knebel Doeberitz M, Rittmuller C, Aengeneyndt F, Jansen-Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical-carcinoma cells - consequences for the phenotype and E6-P53 and E7-Prb interactions. J Virol. 1994;68(5):2811-21.
14. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49(15):3262-73.
15. Bray F, Loos A, McCarron P, Weiderpass E, Arbyn M, Moller H, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005;14(3):677-86.
16. Cuzick J, Clavel C, Petry K, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095-101.
17. Wright Jr TC, Massad S, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Obstet Gynecol. 2007;197(4):346-55.
18. Ho CM, Lee BH, Chang SF, Chien TY, Huang SH, Yan CC, et al. Type-specific human papillomavirus oncogene mRNA levels correlate with the severity of cervical neoplasia. Int J Cancer. 2010;127(3):622-32.
19. Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol. 2011;49(7):2643-50.
20. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol. 2012;50(6):1867-73.
21. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis. 1995;171:1026-30.
22. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005;337:76-84.
23. Tezcan S, Ozgur D, Ulger M, Aslan G, Gurses I, Serin MS, et al. Human papillomavirus genotype distribution and E6/E7 oncogene expression in turkish women with cervical cytological findings. Asian Pac J Cancer Prev. 2014;15(9):3997-4003.
24. Sørbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE. HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions. PLoS One. 2014;18;9(11):e112934.
25. Spathis A, Kottaridi C, Chranioti A, Meristoudis C, Chrelias C, Panayiotides IG, et al. mRNA and DNA detection of human papillomaviruses in women of all ages attending two colposcopy clinics. PLoS One. 2012;7(11):e49205.
26. Perez Castro S, Iñarrea Fernández A, Lamas González MJ, Sarán Diez MT, Cid Lama A, Alvarez Martín MJ, et al. Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA. J Med Virol. 2013;85(6):1063-8.
27. Boulet GA, Micalessi IM, Horvath CA, Benoy IH, Depuydt CE, Bogers JJ. Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification. J Clin Microbiol. 2010;48:2524-9.
28. Ovestad IT, Vennestrøm U, Andersen L, Gudlaugsson E, Munk AC, Malpica A, et al. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN 2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol. 2011;123:278-83.
29. Benevolo M, Terrenato I, Mottolese M, Marandino F, Carosi M, Rollo F, et al. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control. 2011;22(6):869-75.
30. Crow JM. HPV: the global burden. Nature. 2012;488(7413):S2-3.
31. Discacciati MG, da Silva ID, Villa LL, Reis L, Hayashi P, Costa MC, et al. Prognostic value of DNA and mRNA E6/E7 of human papillomavirus in the evolution of cervical intraepithelial neoplasia grade 2. Biomark Insights. 2014;9:15-22.